FibroBiologics stockholders approve reverse stock split and warrant issuances

FibroBiologics, Inc.

Reverse stock split approved at ratio between 1:5 and 1:30, with board discretion; 53.6M votes for, 1.3M against.
Issuance of up to 12.1M shares upon exercise of warrants from Nov 18, 2025 SPA approved (47.9M for, 1.2M against).
Issuance of up to 4.8M shares upon exercise of warrants from Nov 24, 2025 SPA and related engagement letter approved.
Issuance of up to 5.6M shares upon exercise of warrants from Dec 14, 2025 SPA and related engagement letter approved.
Adjournment proposal also passed; all five proposals approved at Feb 20, 2026 special meeting.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.